A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy

Status Completed

Clinical Trial Summary

This is a phase II, open label, experimental medicine study to evaluate the efficacy, safety and mechanism of action of belimumab in subjects with antiphospholipase A2 receptor (PLA2R) autoantibody positive idiopathic membranous glomerulonephropathy (IMGN), and to profile the relationship between biomarkers, autoantibody status and clinical response. 10 milligrams per kilogram (mg/kg) belimumab intravenous (IV) will be administered at weeks 0, 2, and then every 4 weeks, over a 24-week treatment period in subjects with anti-PLA2R antibody positive IMGN followed by a further long term treatment period until subjects reach remission of proteinuria, up to a maximum of 2 years total treatment. All subjects will receive background supportive therapy throughout the study. The dosing frequency will be adjusted to every 2 weeks if the subject's proteinuria as assessed by urinary protein creatinine ratio (PCR) is greater than 1000 milligrams per millimole (mg/mmol) [greater than 10 grams(g)/24 hours (h)], to compensate for loss of belimumab in the urine. Effects on mechanistic markers will be measured by the level of proteinuria, levels of anti-PLA2R antibodies, and various other measures of kidney function. These will be compared to historical data. The pharmacokinetics of belimumab will be measured to confirm dosing in heavily proteinuric subjects. Pharmacodynamic (PD) markers, biomarkers and Quality of Life(QoL) in IMGN subjects will also be investigated. Safety will be assessed by adverse events (AE), clinical laboratory evaluations, and vital signs.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01610492
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	Phase 2
Start date	July 1, 2012
Completion date	September 14, 2016

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01129557` - Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease	Phase 4
Completed	`NCT00199628` - Research Network for Neonatal Diseases Induced by Tissular Fetomaternal Alloimmunization
Active, not recruiting	`NCT05656963` - The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
Completed	`NCT04145440` - Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)	Phase 1/Phase 2
Terminated	`NCT04154787` - Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy	Phase 2
Completed	`NCT00404794` - A Study to Compare Mycophenolate Mofetil and Tacrolimus in the Treatment of Membranous Lupus Nephritis	Phase 3
Completed	`NCT03880643` - Rituximab in Refractory Primary Membranous Nephropathy
Not yet recruiting	`NCT05797051` - Application of Hyperspectral Imaging in the Diagnosis of Glomerular Diseases
Completed	`NCT00135967` - Mycophenolate Mofetil in Membranous Nephropathy	Phase 2/Phase 3
Completed	`NCT00843856` - Mycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous Glomerulonephritis	Phase 4
Recruiting	`NCT01282073` - Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy	Phase 3
Recruiting	`NCT05914155` - Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome	Phase 3
Completed	`NCT00135954` - Treatment of Patients With Idiopathic Membranous Nephropathy	Phase 3
Active, not recruiting	`NCT03018535` - Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy	Phase 3
Completed	`NCT00404833` - Mycophenolate Mofetil in Membranous Nephropathy and Focal Segmental	Phase 3
Withdrawn	`NCT01762852` - Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy	Phase 2